SCHEMBL25613588

SCHEMBL25613588

CC(C)c1ccccc1C1CN(C(N)=O)CCN1C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
ALOX15 P16050 1/20 0.33
DPP4 P27487 1/20 0.32
DPP7 Q9UHL4 1/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TACR1 P25103 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613551 0.89 ITGB2 (0.37) LMNAMEN1KMT2AALOX15TACR1
SCHEMBL25613545 0.88 PKM (0.36) LMNAMEN1KMT2AALOX15DPP4
SCHEMBL25613544 0.86 TACR1 (0.41) LMNAMEN1KMT2AALOX15TACR1
SCHEMBL25613548 0.86 BLM (0.39) LMNAMEN1KMT2ATSHRPOLB
SCHEMBL25629272 0.86 ITGB2 (0.38) MEN1KMT2ATDP1CYP3A4CYP2D6
SCHEMBL25480483 0.82 MEN1 (0.34) LMNAMEN1KMT2AALOX15DPP4
SCHEMBL25613537 0.79 HTR2A (0.39) LMNAMEN1KMT2ACYP1A2CYP3A4
SCHEMBL24774501 0.79 HTR2A (0.39) LMNAMEN1KMT2ACYP1A2CYP3A4
SCHEMBL25613559 0.79 CA12 (0.33) LMNAALOX15POLB
SCHEMBL25613560 0.77 USP1 (0.34) ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 LMNA 1102/4885MEN1 4012/4885KMT2A 2209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.